Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells

Chronic myeloid leukemia (CML) is a hematologic disorder characterized by the oncogene BCR-ABL1, which encodes an oncoprotein with tyrosine kinase activity. Imatinib, a BCR-ABL1 tyrosine kinase inhibitor, performs exceptionally well with minimal toxicity in CML chemotherapy. According to clinical tr...

Full description

Bibliographic Details
Main Authors: Omar Prado-Carrillo, Abner Arenas-Ramírez, Monserrat Llaguno-Munive, Rafael Jurado, Jazmin Pérez-Rojas, Eduardo Cervera-Ceballos, Patricia Garcia-Lopez
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:International Journal of Molecular Sciences
Subjects:
chronic myeloid leukemia
imatinib
tyrosine kinase
ketoconazole
P-glycoprotein
drug efflux transporter
Online Access:https://www.mdpi.com/1422-0067/23/14/7715

Internet

https://www.mdpi.com/1422-0067/23/14/7715

Similar Items